SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ...
Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute uri ...
Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the following segments: Consumer Products and Specialty Pharmaceutical.
Bizcommunity on MSN
Applications closing for Beefmaster’s 2026 agriculture bursary
Applications for the Beefmaster Group’s 2026 academic bursary programme are currently open and will close on 30 December 2025. The bursary targets final-year students in selected agricultural fields ...
Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.
Westlake Village’s Ember LifeSciences raised $16.5M in Series A funding for its cold chain technology. Learn how they are ...
CapsoVision shares jumped 8.4% to $12.55 on Tuesday. Here are some other big stocks recording gains in today’s session. AXT, ...
Cytisinicline likely the best therapy to quit smoking, could be first FDA-approved cessation drug in 20 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback